Seema Singhal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seema Singhal has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
Jyoti Meena
Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India
12 shared publicationsSunesh Kumar
Department of Obstetrics and Gynaecology, Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India
10 shared publicationsJuhi Bharti
Department of Obstetrics and Gynecology, AIIMS, New Delhi, India
8 shared publicationsKallol Kumar Roy
Department Of Obstetrics and Gynaecology, All India Institute of Medical Sciences (AIIMS), B2/20, 3rd Floor, Safdarjung Enclave, New Delhi, India
7 shared publicationsNeena Malhotra
Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India
7 shared publications- Jyoti Meena
Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India
6 shared publications
Latest Publications
- 22 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
Clinical Performance and User-Informed Refinement of an Indigenous HPV Self-Collection Device for Cervical Cancer Screening in Resource-Constrained Settings
Background: HPV self-sampling has improved screening participation but remains constrained by cost and lack of optimised collection devices in resource-constrained settings. This study reports the iterative development of an indigenous self-collection device across successive prototypes. Methods: In this prospective study, women ≥ 30 years were recruited from community and higher-risk clinical cohorts including women living with HIV and colposcopy referrals. Each participant used one of three CERVICHECK™ prototypes (P1–P3) for vaginal self-sampling, followed by physician-collected cervical sampling. Self-collected samples were tested using an indigenous PCR-based HPV assay and physician-collected samples using Cobas 6800. Clinical performance was assessed against histologically confirmed CIN2+ as the primary endpoint. Results: Of 756 enrolled women, 743 paired samples were evaluable; invalidity rate was 1.7%. Iterative device refinement was associated with stepwise improvements in analytical agreement with reference standard (Cohen’s κ: P1:0.49; P2:0.47; P3:0.67). Clinical sensitivity for CIN2+ detection using self-collected samples increased from 40.0% (95%CI 5.3–85.3) with P1 to 75.0% (95%CI 34.9–96.8) with P2 and 93.6% (95%CI 78.6–99.2) with P3. For P3, clinical sensitivity and specificity of self-collected samples was 93.6% (95%CI 78.6–99.2) for CIN2+ and 67.4% (95%CI 58.6–75.4) for ≤CIN1 lesions, yielding a relative clinical sensitivity of 1.0. Reported concerns declined across successive prototypes (P1:47.6%, P2:25.5%, P3:13.4%). Conclusions: Iterative, user-informed refinement of indigenous HPV self-collection device achieved clinically meaningful performance comparable to standard sampling for CIN2+ detection. Impact: Optimised affordable indigenous self-collection solutions may offer scalable and equitable options for implementing HPV-based cervical cancer screening in resource-constrained settings.
- 22 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
Clinical Performance and User-Informed Refinement of an Indigenous HPV Self-Collection Device for Cervical Cancer Screening in Resource-Constrained Settings
Background: HPV self-sampling has improved screening participation but remains constrained by cost and lack of optimised collection devices in resource-constrained settings. This study reports the iterative development of an indigenous self-collection device across successive prototypes. Methods: In this prospective study, women ≥ 30 years were recruited from community and higher-risk clinical cohorts including women living with HIV and colposcopy referrals. Each participant used one of three CERVICHECK™ prototypes (P1–P3) for vaginal self-sampling, followed by physician-collected cervical sampling. Self-collected samples were tested using an indigenous PCR-based HPV assay and physician-collected samples using Cobas 6800. Clinical performance was assessed against histologically confirmed CIN2+ as the primary endpoint. Results: Of 756 enrolled women, 743 paired samples were evaluable; invalidity rate was 1.7%. Iterative device refinement was associated with stepwise improvements in analytical agreement with reference standard (Cohen’s κ: P1:0.49; P2:0.47; P3:0.67). Clinical sensitivity for CIN2+ detection using self-collected samples increased from 40.0% (95%CI 5.3–85.3) with P1 to 75.0% (95%CI 34.9–96.8) with P2 and 93.6% (95%CI 78.6–99.2) with P3. For P3, clinical sensitivity and specificity of self-collected samples was 93.6% (95%CI 78.6–99.2) for CIN2+ and 67.4% (95%CI 58.6–75.4) for ≤CIN1 lesions, yielding a relative clinical sensitivity of 1.0. Reported concerns declined across successive prototypes (P1:47.6%, P2:25.5%, P3:13.4%). Conclusions: Iterative, user-informed refinement of indigenous HPV self-collection device achieved clinically meaningful performance comparable to standard sampling for CIN2+ detection. Impact: Optimised affordable indigenous self-collection solutions may offer scalable and equitable options for implementing HPV-based cervical cancer screening in resource-constrained settings.
- 9 April 2026
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 15 (5) , 340-352
Role of ascitic and peritoneal fluid effusion cytology in predicting intraperitoneal metastasis of malignant ovarian germ cell tumours
- 9 April 2026
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 15 (5) , 340-352
Role of ascitic and peritoneal fluid effusion cytology in predicting intraperitoneal metastasis of malignant ovarian germ cell tumours
- 5 January 2026
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 24 (1) , 19
Navigating Arterio-venous Malformations in Placental Site Trophoblastic Tumour: Dilemmas and Successful Management
- 5 January 2026
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 24 (1) , 19
Navigating Arterio-venous Malformations in Placental Site Trophoblastic Tumour: Dilemmas and Successful Management
- 31 December 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (12) , e267152
Cutaneous metastases from vulvar carcinoma: rare phenomenon with fatal outcome
- 31 December 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (12) , e267152
Cutaneous metastases from vulvar carcinoma: rare phenomenon with fatal outcome
- Open Access
- 1 December 2025
- Published by Korean Society of Clinical Oncology in Korean Journal of Clinical Oncology
- Vol. 21 (3) , 164-168
Primary Ewing sarcoma of the uterine cervix: a case report and comprehensive review
Primary Ewing sarcoma of the uterine cervix is an exceptionally rare and aggressive malignancy, with only 34 cases reported in the literature. Early recognition and prompt multimodal treatment are essential due to its poor prognosis. We report a case involving a 32-year-old multiparous woman who presented with foul-smelling vaginal discharge and irregular bleeding. Clinical examination revealed a 6×6 cm friable cervical mass extending into the upper vagina. Imaging demonstrated an FDG-avid cervical mass with regional lymphadenopathy. Histopathological analysis, supported by immunohistochemistry and fluorescence in situ hybridization, confirmed Ewing sarcoma with EWSR1 gene rearrangement. The patient received neoadjuvant chemotherapy with VDC (vincristine, doxorubicin, cyclophosphamide) and PIE (cisplatin, ifosfamide, etoposide) regimens, followed by surgical resection, adjuvant chemotherapy, and pelvic radiotherapy. Although initial disease control was achieved, the patient experienced disease recurrence with distant metastases after a 7-month disease-free interval and succumbed to the illness 9 months after diagnosis. This case underscores the importance of including Ewing sarcoma in the differential diagnosis of rapidly growing cervical tumors, particularly in young women. A multidisciplinary approach involving early molecular diagnostics and aggressive combined therapy is critical to improving clinical outcomes in such rare and aggressive cases.
- 1 December 2025
- Published by Korean Society of Clinical Oncology in Korean Journal of Clinical Oncology
- Vol. 21 (3) , 164-168
Open AccessPrimary Ewing sarcoma of the uterine cervix: a case report and comprehensive review
Primary Ewing sarcoma of the uterine cervix is an exceptionally rare and aggressive malignancy, with only 34 cases reported in the literature. Early recognition and prompt multimodal treatment are essential due to its poor prognosis. We report a case involving a 32-year-old multiparous woman who presented with foul-smelling vaginal discharge and irregular bleeding. Clinical examination revealed a 6×6 cm friable cervical mass extending into the upper vagina. Imaging demonstrated an FDG-avid cervical mass with regional lymphadenopathy. Histopathological analysis, supported by immunohistochemistry and fluorescence in situ hybridization, confirmed Ewing sarcoma with EWSR1 gene rearrangement. The patient received neoadjuvant chemotherapy with VDC (vincristine, doxorubicin, cyclophosphamide) and PIE (cisplatin, ifosfamide, etoposide) regimens, followed by surgical resection, adjuvant chemotherapy, and pelvic radiotherapy. Although initial disease control was achieved, the patient experienced disease recurrence with distant metastases after a 7-month disease-free interval and succumbed to the illness 9 months after diagnosis. This case underscores the importance of including Ewing sarcoma in the differential diagnosis of rapidly growing cervical tumors, particularly in young women. A multidisciplinary approach involving early molecular diagnostics and aggressive combined therapy is critical to improving clinical outcomes in such rare and aggressive cases.
- Open Access
- 1 December 2025
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 26 (12) , 4575-4583
Multimodal Prehabilitation in Indian Women with Advanced Ovarian Cancer: Enhancing Nutritional, Psychological, and Surgical Recovery
Malnutrition is common among women with gynecologic cancers, particularly advanced ovarian cancer, and adversely impacts treatment tolerance, surgical recovery, and quality of life. The neoadjuvant chemotherapy (NACT) phase provides a unique opportunity to introduce prehabilitation interventions to improve perioperative outcomes. To evaluate the feasibility and impact of a culturally tailored, home-based multimodal prehabilitation program on perioperative outcomes in Indian women with advanced ovarian cancer undergoing NACT. Methods: Sixty women planned for NACT were enrolled and allocated to either a prehabilitation group (n = 30) or control group (n = 30). The intervention include yoga-based physiotherapy, individualized nutritional counseling, and psychological support. Outcomes assessed pre- and post-NACT included body mass index (BMI), hemoglobin, serum albumin, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), skeletal muscle index (SMI), Hospital Anxiety and Depression Scale (HADS) scores, in each group and between group comparisons of perioperative outcomes. Both groups showed significant within-group improvements in nutritional and inflammatory markers. Between-group comparisons revealed a smaller decline in BMI (-1.29 vs. -4.51; p < 0.001) and a greater reduction in HADS scores (-4.5 vs. -1.5; p =0.013) in the prehabilitation group. Hospital stay was significantly shorter in the prehabilitation group (median: 4 vs. 5.5 days; p = 0.005), while reductions in intraoperative blood loss and postoperative complications did not reach statistical significance. Greater physiotherapy session attendance correlated with reduced BMI loss (ρ = -0.4187, p = 0.022). Multivariable analysis showed that prehabilitation and physiotherapy adherence were associated with smaller BMI declines, and prehabilitation reduced the odds of prolonged hospitalization. Implementing a culturally adapted multimodal prehabilitation program is feasible and improves short-term nutritional, psychological, and perioperative outcomes in women undergoing NACT for advanced ovarian cancer.
- 1 December 2025
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 26 (12) , 4575-4583
Open AccessMultimodal Prehabilitation in Indian Women with Advanced Ovarian Cancer: Enhancing Nutritional, Psychological, and Surgical Recovery
Malnutrition is common among women with gynecologic cancers, particularly advanced ovarian cancer, and adversely impacts treatment tolerance, surgical recovery, and quality of life. The neoadjuvant chemotherapy (NACT) phase provides a unique opportunity to introduce prehabilitation interventions to improve perioperative outcomes. To evaluate the feasibility and impact of a culturally tailored, home-based multimodal prehabilitation program on perioperative outcomes in Indian women with advanced ovarian cancer undergoing NACT. Methods: Sixty women planned for NACT were enrolled and allocated to either a prehabilitation group (n = 30) or control group (n = 30). The intervention include yoga-based physiotherapy, individualized nutritional counseling, and psychological support. Outcomes assessed pre- and post-NACT included body mass index (BMI), hemoglobin, serum albumin, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), skeletal muscle index (SMI), Hospital Anxiety and Depression Scale (HADS) scores, in each group and between group comparisons of perioperative outcomes. Both groups showed significant within-group improvements in nutritional and inflammatory markers. Between-group comparisons revealed a smaller decline in BMI (-1.29 vs. -4.51; p < 0.001) and a greater reduction in HADS scores (-4.5 vs. -1.5; p =0.013) in the prehabilitation group. Hospital stay was significantly shorter in the prehabilitation group (median: 4 vs. 5.5 days; p = 0.005), while reductions in intraoperative blood loss and postoperative complications did not reach statistical significance. Greater physiotherapy session attendance correlated with reduced BMI loss (ρ = -0.4187, p = 0.022). Multivariable analysis showed that prehabilitation and physiotherapy adherence were associated with smaller BMI declines, and prehabilitation reduced the odds of prolonged hospitalization. Implementing a culturally adapted multimodal prehabilitation program is feasible and improves short-term nutritional, psychological, and perioperative outcomes in women undergoing NACT for advanced ovarian cancer.
- 16 August 2025
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23 (3) , 1-9
Vaginal Clear Cell Carcinoma Without Diethylstilbestrol Exposure: A Rare Case and Review of 38 Reported Cases
- 16 August 2025
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23 (3) , 1-9
Vaginal Clear Cell Carcinoma Without Diethylstilbestrol Exposure: A Rare Case and Review of 38 Reported Cases
- 31 May 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 171 (3) , 1310-1316
Cachexia in gynecologic cancers: The role of biomarkers and cachexia index
Background: Cancer cachexia, a metabolic syndrome causing muscle loss, inflammation, and malnutrition, adversely affects prognosis and treatment in cancer patients. Despite extensive studies in other malignancies, cachexia remains underexplored in gynecologic cancers, particularly in India. This study evaluates the cachexia index (CXI) in gynecologic cancer patients and its association with Activin A and Myostatin. Methods: In this prospective observational study, 160 women with gynecologic malignancies were assessed for cachexia using Fearon's criteria, the global leadership initiative on malnutrition (GLIM) definition, and CXI, which integrates skeletal muscle index (SMI), albumin, and neutrophil‐to‐lymphocyte ratio (NLR). Serum Activin A and Myostatin were measured via enzyme‐linked immunosorbent assay. A subgroup of 30 ovarian cancer patients received nutritional and physical prehabilitation, with biomarker reassessment post‐intervention. Results: Cachexia prevalence was 22.50% (Fearon's) and 56.25% (GLIM). The median CXI was 56.74, with 33.75% having CXI < 41, indicating severe cachexia. CXI < 41 was correlated with advanced disease ( P = 0.000), lower body mass index ( P = 0.034), reduced SMI ( P = 0.000), and elevated inflammatory markers. Activin A was significantly higher in severe cachexia ( P = 0.024), while Myostatin showed no correlation. Prehabilitation significantly improved CXI ( P = 0.0001) and reduced Activin A and Myostatin ( P = 0.0003, P < 0.0001). In multivariable analysis, platelet‐to‐lymphocyte ratio emerged as the only independent predictor of low CXI (odds ratio 1.0145; 95% confidence interval 1.0081–1.0210; P < 0.001), while Activin A showed a trend toward significance ( P = 0.088). Conclusion: CXI provides a comprehensive cachexia assessment in gynecologic cancers. Elevated Activin A is linked to muscle degradation. Prehabilitation improves CXI and reduces cachexia biomarkers, emphasizing its therapeutic potential. Further validation of CXI and biomarkers may enhance cachexia diagnosis and management.
- 31 May 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 171 (3) , 1310-1316
Cachexia in gynecologic cancers: The role of biomarkers and cachexia index
Background: Cancer cachexia, a metabolic syndrome causing muscle loss, inflammation, and malnutrition, adversely affects prognosis and treatment in cancer patients. Despite extensive studies in other malignancies, cachexia remains underexplored in gynecologic cancers, particularly in India. This study evaluates the cachexia index (CXI) in gynecologic cancer patients and its association with Activin A and Myostatin. Methods: In this prospective observational study, 160 women with gynecologic malignancies were assessed for cachexia using Fearon's criteria, the global leadership initiative on malnutrition (GLIM) definition, and CXI, which integrates skeletal muscle index (SMI), albumin, and neutrophil‐to‐lymphocyte ratio (NLR). Serum Activin A and Myostatin were measured via enzyme‐linked immunosorbent assay. A subgroup of 30 ovarian cancer patients received nutritional and physical prehabilitation, with biomarker reassessment post‐intervention. Results: Cachexia prevalence was 22.50% (Fearon's) and 56.25% (GLIM). The median CXI was 56.74, with 33.75% having CXI < 41, indicating severe cachexia. CXI < 41 was correlated with advanced disease ( P = 0.000), lower body mass index ( P = 0.034), reduced SMI ( P = 0.000), and elevated inflammatory markers. Activin A was significantly higher in severe cachexia ( P = 0.024), while Myostatin showed no correlation. Prehabilitation significantly improved CXI ( P = 0.0001) and reduced Activin A and Myostatin ( P = 0.0003, P < 0.0001). In multivariable analysis, platelet‐to‐lymphocyte ratio emerged as the only independent predictor of low CXI (odds ratio 1.0145; 95% confidence interval 1.0081–1.0210; P < 0.001), while Activin A showed a trend toward significance ( P = 0.088). Conclusion: CXI provides a comprehensive cachexia assessment in gynecologic cancers. Elevated Activin A is linked to muscle degradation. Prehabilitation improves CXI and reduces cachexia biomarkers, emphasizing its therapeutic potential. Further validation of CXI and biomarkers may enhance cachexia diagnosis and management.
- 8 April 2025
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 310, 113964
Nutritional assessment in gynecological cancers: Experience from an Indian tertiary care center
- 8 April 2025
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 310, 113964
Nutritional assessment in gynecological cancers: Experience from an Indian tertiary care center